- Home
- TRMD vs SWTX Comparison
TRMD vs SWTX Comparison
Compare TRMD & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- SWTX
- Stock Information
- Founded
- TRMD 1889
- SWTX 2017
- Country
- TRMD United Kingdom
- SWTX United States
- Employees
- TRMD N/A
- SWTX N/A
- Industry
- TRMD Marine Transportation
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- SWTX Health Care
- Exchange
- TRMD Nasdaq
- SWTX Nasdaq
- Market Cap
- TRMD 1.9B
- SWTX 2.8B
- IPO Year
- TRMD N/A
- SWTX 2019
- Fundamental
- Price
- TRMD $19.30
- SWTX $37.03
- Analyst Decision
- TRMD Buy
- SWTX Strong Buy
- Analyst Count
- TRMD 1
- SWTX 5
- Target Price
- TRMD $48.00
- SWTX $67.00
- AVG Volume (30 Days)
- TRMD 1.2M
- SWTX 1.0M
- Earning Date
- TRMD 11-07-2024
- SWTX 02-25-2025
- Dividend Yield
- TRMD 24.41%
- SWTX N/A
- EPS Growth
- TRMD N/A
- SWTX N/A
- EPS
- TRMD 7.70
- SWTX N/A
- Revenue
- TRMD $1,641,593,000.00
- SWTX $135,487,000.00
- Revenue This Year
- TRMD N/A
- SWTX $3,426.90
- Revenue Next Year
- TRMD N/A
- SWTX $88.92
- P/E Ratio
- TRMD $2.53
- SWTX N/A
- Revenue Growth
- TRMD 3.90
- SWTX N/A
- 52 Week Low
- TRMD $17.77
- SWTX $28.21
- 52 Week High
- TRMD $40.47
- SWTX $53.92
- Technical
- Relative Strength Index (RSI)
- TRMD 40.05
- SWTX 44.60
- Support Level
- TRMD $17.77
- SWTX $34.36
- Resistance Level
- TRMD $19.76
- SWTX $37.80
- Average True Range (ATR)
- TRMD 0.53
- SWTX 1.69
- MACD
- TRMD 0.29
- SWTX -0.63
- Stochastic Oscillator
- TRMD 64.44
- SWTX 23.94
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.